<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01384747</url>
  </required_header>
  <id_info>
    <org_study_id>CVRF2011-03</org_study_id>
    <nct_id>NCT01384747</nct_id>
  </id_info>
  <brief_title>Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)</brief_title>
  <official_title>A Randomized, Double-blind Study of Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioVascular Research Foundation, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Fimasartan will be more beneficial in stabilizing the plaque vulnerability compared to&#xD;
           control group in deferred coronary lesions.&#xD;
&#xD;
        -  Fimasartan will be more beneficial in reducing total plaque volume compared to control&#xD;
           group in deferred coronary lesions.&#xD;
&#xD;
        -  Fimasartan will be more beneficial in reducing functional impairment of stenotic lesions&#xD;
           (assessed by FFR:Fractional Flow Reserve) in deferred coronary lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, double-blind, randomized clinical study with enrollment of patients over at&#xD;
      least 18 years of age who require coronary angiography for a clinical indication with&#xD;
      hypertension defined as systolic blood pressure &gt;140mmHg or diastolic blood pressure &gt;90mmHg.&#xD;
      Inclusion requires at least one deferred coronary lesion with 1) visually-estimated&#xD;
      angiographic %diameter stenosis 20-50% or 2) %diameter stenosis &gt;50% without any evidence of&#xD;
      inducible ischemia. The target vessel for IVUS interrogation must not have undergone&#xD;
      angioplasty (deferred lesion) nor have more than 50% luminal narrowing throughout a target&#xD;
      segment. Patients meeting inclusion criteria without any exclusion criteria will be&#xD;
      randomized 1:1 (Fimasartan 60-120 mg vs placebo). All subjects will be followed up at 1 year&#xD;
      for serial VH-IVUS and conventional IVUS evaluation. Also, OCT sub-study will be performed in&#xD;
      selected patients with lesions at least 20 mm distally located from coronary ostium. All&#xD;
      patients will be blindly assigned to control and Fimasartan once daily as 1:1 ratio and are&#xD;
      prescribed for 1year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in percent necrotic core (NC) volume of plaque by VH (Virtual Histology) in the &quot;target segment&quot; (within deferred vessel)</measure>
    <time_frame>baseline and 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of total atheroma volume (TAV) and percent atheroma volume (PAV) of the target segment and the most diseased 10-mm segment (normalized to different segment length) with the largest plaque volume</measure>
    <time_frame>baseline and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in minimal lumen area (MLA) in target segment</measure>
    <time_frame>baseline and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of absolute area or percentages (%) of each plaque VH composition (fibrotic, fibrofatty, dense calcium, necrotic core) at minimal lumen area (MLA) and largest necrotic core area within the target segment</measure>
    <time_frame>baseline and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of VH-IVUS (Intra Vascular UltraSound) detected plaque type from baseline</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of percentage (%) of OCT (Optical Coherence Tomography)-defined TCFA (Thin Cap Fibrotic Atheroma) within the target segment from baseline</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of composition of OCT-defined fibrous, fibro-calcific, and lipid-rich plaque within the target segment</measure>
    <time_frame>baseline and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of OCT-defined fibrous cap thickness, the presence of plaque disruption, calcification or intraluminal thrombus within the target segment</measure>
    <time_frame>baseline and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of FFR in target segment from baseline</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systolic and diastolic blood pressure</measure>
    <time_frame>at 1 year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in high sensitive CRP (C-Reactive Protein)from baseline</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Fimasartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial dose will be started with 60mg per day. At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Initial dose will be started with 60mg per day. At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan</intervention_name>
    <description>60-120mg/day (target dose) of Fimasartan will be administered for the study period (till the follow-up angiography)</description>
    <arm_group_label>Fimasartan</arm_group_label>
    <other_name>Kanarb Tab.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hypertensive patients (systolic blood pressure &gt;140mmHg or diastolic blood pressure&#xD;
             &gt;90mmHg) or medically treated hypertension with normal blood pressure who undergo&#xD;
             coronary angiography with clinical indications&#xD;
&#xD;
          2. 18 &lt; Age &lt; 85&#xD;
&#xD;
          3. Patient who has received informed consent&#xD;
&#xD;
          4. at least one deferred coronary lesion with 1) visually-estimated angiographic&#xD;
             %diameter stenosis 20-50% or 2) %diameter stenosis &gt;50% without any evidence of&#xD;
             inducible ischemia (FFR â‰¥ 0.8 or negative perfusion defect on thallium scan or&#xD;
             negative treadmill test)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Planned cardiac surgery (e.g., CABG, valve repair or replacement, or aneurysmectomy)&#xD;
             or planned major non-cardiac surgery within the study period&#xD;
&#xD;
          2. Planned performance of PCI or CABG in the target vessel or its branches containing the&#xD;
             index&#xD;
&#xD;
          3. Evidence of congestive heart failure, or left ventricular ejection fraction &lt; 40%&#xD;
&#xD;
          4. Stroke or resuscitated sudden death in the past 6 months&#xD;
&#xD;
          5. Chronic disease requiring treatment with oral, intravenous, or intra-articular&#xD;
             corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible)&#xD;
&#xD;
          6. A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in&#xD;
             the past 3 years or current treatment for the active cancer&#xD;
&#xD;
          7. Any clinically significant abnormality identified at the screening visit, physical&#xD;
             examination, laboratory tests, or electrocardiogram which, in the judgment of the&#xD;
             Investigator, would preclude safe completion of the study&#xD;
&#xD;
          8. Significant renal disease manifested by serum creatinine &gt; 1.5 mg/dL&#xD;
&#xD;
          9. Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation&#xD;
             (ALT or AST &gt; 3 times upper limit of normal)&#xD;
&#xD;
         10. Active hepatitis B or C or carrier&#xD;
&#xD;
         11. Hypotension (systolic blood pressure &lt;90 mmHg)&#xD;
&#xD;
         12. Patients already taking ACE inhibitors or ARBs&#xD;
&#xD;
         13. Patients with STEMI requiring primary PCI&#xD;
&#xD;
         14. Patients pregnant or breast-feeding or child-bearing potential&#xD;
&#xD;
         15. Patients who are lack of intention for effective contraception&#xD;
&#xD;
         16. Patients with history of previous enrollment into a clinical trials within 3 months&#xD;
&#xD;
         17. Allergic or contraindicated to Angiotensin II antagonists&#xD;
&#xD;
         18. History of any arterial bypass or angioplastic intervention involving the target&#xD;
             vessel&#xD;
&#xD;
         19. Luminal narrowing in the left main &gt; 50% by visual inspection of angiogram&#xD;
&#xD;
         20. Visually-estimated angiographic reference segment diameter of &lt;2.75mm or &gt;4.0 mm&#xD;
&#xD;
         21. Presence of thrombus or complex plaque morphology in the target vessel that suggests a&#xD;
             high likelihood of distal embolism&#xD;
&#xD;
         22. Severe tortuosity of the target vessel or any other anatomical reasons that the&#xD;
             investigator deems&#xD;
&#xD;
         23. Inappropriate for IVUS procedures. Vessel with thrombus (on GS-IVUS), moderate or&#xD;
             severe calcification, angulation&#xD;
&#xD;
         24. Culprit vessel in AMI&#xD;
&#xD;
         25. RWMA (Regional Wall Motion Abnormality) or scar tissue in the territory subtended by&#xD;
             the studied lesion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Jung Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <zip>682-714</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 24, 2011</study_first_submitted>
  <study_first_submitted_qc>June 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2011</study_first_posted>
  <last_update_submitted>June 19, 2018</last_update_submitted>
  <last_update_submitted_qc>June 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CardioVascular Research Foundation, Korea</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>MD,PhD, Chairman,Heart Institute, Asan Medical Center,University of Ulsan,College of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is not a publicly funded trial.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

